Notable RET Inhibitor Trials Underway

Video

Transcript:

Related Videos
A panel of 5 experts on lung cancer seated at a long table
Joshua K. Sabari, MD, and Marina Chiara Garassino, MD, experts on non-small cell lung cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Catherine Ann Shu, MD
Christine Bestvina, MD
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
Related Content
Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility

Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility

December 8th 2023
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
The addition of the novel PD-1 inhibitor serplulimab to carboplatin and nab-paclitaxel significantly and consistently prolonged progression-free survival and overall survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer, according to updated data from the phase 3 ASTRUM-004 trial.

Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC

December 5th 2023
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
No Survival Benefit With Pemetrexed Plus Cisplatin Vs Vinorelbine in NSCLC | Image Credit: © yodiyim - stock.adobe.com

Adding Pemetrexed to Cisplatin Does Not Result in Survival Benefit Over Vinorelbine in NSCLC

December 2nd 2023
Article
Lyudmila A. Bazhenova, MD

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

November 30th 2023
Article